The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.
Related stories
SEC proposes performance fees for retail funds in private markets push
This is the big risk that stock investors should be watching as rising bond yields menace markets
The volunteers baking birthday cakes for children
Major car rivals are teaming up to solve the biggest EV roadblock: Reliable charging
Americans get back to their spending ways. Economy might be speeding up again.
How Amazon’s stock can fight off the AI threat and soar 46%